Skip to content

NEOGAP winner of Business Sweden’s Catalyst Program


PRESS RELEASE. Swedish biotechnology company NEOGAP Therapeutics has been selected winner of Business Sweden’s Catalyst Program 2023. NEOGAP will gain a powerful stepping stone towards international growth, including a tailored market entry project worth SEK 250,000 to support and accelerate its international growth journey.

NEOGAP Therapeutics has been awarded as one of three winners of Business Sweden’s Catalyst Program 2023 in the category of Deep Tech. Business Sweden’s Catalyst Program is a scale-up program for Sweden’s most innovative and promising companies. Candidates that successfully make it through the selection process gain tailored support for international growth, including commercialisation support, advice, and coaching in a chosen market.

“We are very pleased and proud to see that NEOGAP was selected as one of the most promising Swedish companies by the Catalyst committee. We look forward to collaborating with Business Sweden, exploring strategic international partnerships, and finding potential investors in our innovative cell therapy pTTL,” says Samuel Svensson, CEO of NEOGAP.

The program identifies Swedish companies that have the strongest prerequisites to scale up globally. As a winner of the Catalyst Program, NEOGAP will receive a tailored market entry project worth SEK 250,000 to support and accelerate its international growth journey.

“Business Sweden would like to congratulate NEOGAP for being selected as one of Sweden’s most innovative biotech and Deep Tech companies. At Business Sweden, we are happy to support NEOGAP long-term in their internationalisation journey. This is an example of how Business Sweden can add value to Sweden’s most innovative biotech companies” says Jonas Thulin, Program Manager at Business Sweden.

Business Sweden is commissioned by the government and the Swedish industry to help Swedish companies grow global sales, and international companies invest and expand in Sweden. For more information, please visit

The Catalyst committee manages the selection process, consisting of a mix of external industry experts and angel investors.

For more information, please contact:
Samuel Svensson, CEO
Phone: +46 733 54 21 94

About NEOGAP Therapeutics
NEOGAP Therapeutics is a Swedish clinical-stage biotechnology company focused on developing personalised cancer immunotherapy using patient’s own cells. The therapy is based on the company’s two technologies PIOR® and EpiTCer®. PIOR® is sophisticated software that uses DNA sequencing data from the patient and machine learning algorithms to select tumour-specific mutations. Then, EpiTCer® is used to multiply T cells that can recognise and attack the selected tumor-specific targets. NEOGAP is located at the Centre for Molecular Medicine at the Karolinska Institute in Stockholm. To learn more about NEOGAP and its cutting-edge research, please visit the company’s website at and follow NEOGAP on LinkedIn.

Access our Swedish press release on Cision’s press room
To read our press release in Swedish, please navigate to our press room on Cision, where you can access all of our latest news and announcements.